

[illegible]

DATE CONSIDERED

Substitute for form 1449B/PTO FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	ATTORNEY DOCKET NO. 3474.1001-011	APPLICATION NO. 10/791,223	
LISTING OF REFERENCES January 3, 2008 (Use several sheets if necessary)	FIRST NAMED INVENTOR Mel H. Epstein	FILING DATE March 2, 2004	
	EXAMINER Brian Yong S. Kwon	CONFIRMATION NO. 3953	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C24	Birks, J. and Flicker, L., "Selegiline For Alzheimer's Disease," (Cochrane Review). In: <i>The Cochrane Library, Issue 4</i> ; pp. 1-35 (2002). Oxford: Update Software.
C26	Bishop, J., <i>et al.</i> , "Toxicology and Carcinogenesis Studies of <i>dl</i> -Amphetamine Sulfate in F344/N Rats and B6C3F ₁ Mice," (Technical Report Series No. 387). Research Triangle Park, NC: National Toxicology Program, U. S. Department of Health and Human Services; pp. 3-185 (1991).
C286	Brady, <i>et al.</i> , "Stroke Risk Predicts Verbal Fluency Decline in Healthy Older Men," <i>J Gerontol B Psychol Sci Soc Sci</i> , 56:P340-P346 (2001).
C287	Caldarusa-Dalton, "Parkinson's Disease: Current and Future Treatments," http://sulcus.berkeley.edu/mcb/165_001/papers/manuscripts/_519.html ; pp 1-9 (1999).
C288	Hill, "What is Neuroprotection?" <i>Medical News Today</i> , www.medicalnewstoday.com (10/09/2006).
C289	Iudicello, <i>et al.</i> , "Verbal Fluency in HIV Infection: A Meta-Analytic Review," <i>J Int Neuropsychol Soc</i> , 13: 183-189 (2007).
C290	The Kenneth T. and Eileen L. Norris Laboratory for Neuroscience Research, "Alzheimer's Disease," <i>University of Southern California School of Pharmacy</i> , pp 1-3 (2007).
C291	Khan, "Can Clinical Outcomes be used to Detect Neuroprotection in Multiple Sclerosis?" <i>Neurology</i> , 68:S64-S71, (2007).
C292	Piérard, <i>et al.</i> , "Declarative Memory Impairments following a Military Combat Course: Parallel Neuropsychological and Biochemical Investigations," <i>Neuropsychobiology</i> , 49:210-17 (2004).
C293	Rajan, "Senior Moments: The Neurobiology of Memory and Aging," <i>Serendip</i> , pp 1-4 (2002).
C294	Goodman, <i>et al.</i> , <i>Goodman and Gilman's The Pharmacological Basis of Therapeutics</i> , 9 th Ed. pp. 202 and 221 (1996).
C295	Rohatagi, <i>et al.</i> , "Pharmacokinetic Evaluation of a Selegiline Pulsatile Oral Delivery System," <i>Biopharmaceutics & Drug Disposition</i> , 18(8):665-680 (1997).

EXAMINER	DATE CONSIDERED
----------	-----------------